Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasm Metastasis

ClinicalTrials.gov lists 4,096 trials for Neoplasm Metastasis or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 127.

MeSH D009362 Neoplasms Neoplasm C04 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 967 Phase 1/2 Phase 1/2 393 Phase 2 Phase 2 1,076 Phase 2/3 Phase 2/3 52 Phase 3 Phase 3 320 Phase 4 Phase 4 62 Not applicable Not applicable 541 Observational Observational 676 Phase 1 Phase 1 967 Phase 1/2 Phase 1/2 393 Phase 2 Phase 2 1,076 Phase 2/3 Phase 2/3 52 Phase 3 Phase 3 320 Phase 4 Phase 4 62 Not applicable Not applicable 541 Observational Observational 676

Trials per phase (log scale)

1 more section with rows

3,582 of the 4,096 trials are tagged with Neoplasm Metastasis itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplasm Metastasis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasm Metastasis trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 278

1990: 1 trials (Observational 1) 1991: 3 trials (Phase 3 1, Phase 1 2) 1992: 4 trials (Phase 3 2, Phase 1 2) 1993: 2 trials (Phase 1/2 1, Phase 1 1) 1994: 6 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 1, Phase 1 1) 1995: 4 trials (Phase 2 2, Phase 1 2) 1996: 8 trials (Phase 3 5, Phase 2 2, Phase 1 1) 1997: 11 trials (Observational 1, Not applicable 3, Phase 3 1, Phase 2 1, Phase 1 5) 1998: 22 trials (Phase 3 6, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 4) 1999: 34 trials (Observational 3, Phase 3 5, Phase 2 14, Phase 1/2 3, Phase 1 9) 2000: 29 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 5, Phase 2 8, Phase 1/2 1, Phase 1 10) 2001: 44 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 7, Phase 1 10) 2002: 50 trials (Not applicable 1, Phase 4 3, Phase 3 16, Phase 2/3 1, Phase 2 21, Phase 1/2 5, Phase 1 3) 2003: 61 trials (Observational 9, Not applicable 1, Phase 4 2, Phase 3 10, Phase 2/3 1, Phase 2 29, Phase 1/2 2, Phase 1 7) 2004: 76 trials (Observational 7, Not applicable 3, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 31, Phase 1/2 5, Phase 1 15) 2005: 104 trials (Observational 10, Not applicable 4, Phase 4 2, Phase 3 12, Phase 2 46, Phase 1/2 12, Phase 1 18) 2006: 128 trials (Other 1, Observational 12, Not applicable 7, Phase 4 3, Phase 3 18, Phase 2 53, Phase 1/2 8, Phase 1 26) 2007: 120 trials (Observational 16, Not applicable 4, Phase 4 1, Phase 3 8, Phase 2/3 3, Phase 2 60, Phase 1/2 3, Phase 1 25) 2008: 108 trials (Observational 15, Not applicable 9, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 31, Phase 1/2 11, Phase 1 30) 2009: 137 trials (Observational 19, Not applicable 11, Phase 3 11, Phase 2/3 1, Phase 2 52, Phase 1/2 13, Phase 1 30) 2010: 147 trials (Observational 28, Not applicable 21, Phase 4 2, Phase 3 7, Phase 2 41, Phase 1/2 9, Phase 1 39) 2011: 140 trials (Observational 15, Not applicable 12, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 2 47, Phase 1/2 8, Phase 1 43) 2012: 149 trials (Observational 23, Not applicable 15, Phase 4 3, Phase 3 16, Phase 2/3 4, Phase 2 40, Phase 1/2 10, Phase 1 38) 2013: 162 trials (Observational 28, Not applicable 19, Phase 4 4, Phase 3 8, Phase 2 52, Phase 1/2 12, Phase 1 39) 2014: 178 trials (Observational 33, Not applicable 31, Phase 4 3, Phase 3 10, Phase 2/3 3, Phase 2 49, Phase 1/2 15, Phase 1 34) 2015: 142 trials (Observational 32, Not applicable 27, Phase 4 4, Phase 3 12, Phase 2/3 3, Phase 2 25, Phase 1/2 8, Phase 1 31) 2016: 183 trials (Observational 34, Not applicable 34, Phase 4 2, Phase 3 11, Phase 2/3 3, Phase 2 38, Phase 1/2 12, Phase 1 49) 2017: 159 trials (Observational 26, Not applicable 31, Phase 4 3, Phase 3 8, Phase 2/3 3, Phase 2 37, Phase 1/2 14, Phase 1 37) 2018: 172 trials (Observational 34, Not applicable 29, Phase 4 3, Phase 3 8, Phase 2/3 3, Phase 2 38, Phase 1/2 21, Phase 1 36) 2019: 189 trials (Observational 42, Not applicable 25, Phase 4 3, Phase 3 11, Phase 2/3 4, Phase 2 46, Phase 1/2 19, Phase 1 39) 2020: 194 trials (Observational 38, Not applicable 33, Phase 3 7, Phase 2 42, Phase 1/2 27, Phase 1 47) 2021: 278 trials (Observational 49, Not applicable 51, Phase 4 2, Phase 3 19, Phase 2/3 3, Phase 2 55, Phase 1/2 38, Phase 1 61) 2022: 225 trials (Observational 50, Not applicable 41, Phase 4 1, Phase 3 15, Phase 2 32, Phase 1/2 34, Phase 1 52) 2023: 202 trials (Observational 36, Not applicable 35, Phase 3 11, Phase 2/3 1, Phase 2 31, Phase 1/2 29, Phase 1 59) 2024: 194 trials (Observational 47, Not applicable 27, Phase 4 2, Phase 3 9, Phase 2/3 2, Phase 2 37, Phase 1/2 9, Phase 1 61) 2025: 178 trials (Observational 26, Not applicable 27, Phase 4 3, Phase 3 16, Phase 2/3 6, Phase 2 28, Phase 1/2 17, Phase 1 55)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 207
2025 178
2024 194
2023 202
2022 225
2021 278
2020 194
2019 189
2018 172
2017 159

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 551 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 2,389 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasm Metastasis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 967
Phase 1/2 393
Phase 2 1,076
Phase 2/3 52
Phase 3 320
Phase 4 62
Not applicable 541
Observational 676
Expanded access 9

How many Neoplasm Metastasis trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 146
Recruiting 611
Enrolling by invitation 10
Active, not recruiting 272
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasm Metastasis trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 127
Eli Lilly and Company 72
AstraZeneca 53
Novartis Pharmaceuticals 42
Pfizer 41

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Neoplasm Metastasis? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PEMBROLIZUMAB 139
(nab)-paclitaxel 120
"Capecitabine" 91
NIVOLUMAB 85
OXALIPLATIN 74

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Gemcitabine/Gemzar 120
Bevacizumab 1 95
or carboplatin 82
Fluorouracile 81
Docetetaxel 78

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasm Metastasis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,751 229
Vomiting 1,087 283
Pyrexia 1,004 195
Diarrhoea 873 159
Dyspnoea 870 175

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasm Metastasis? (3,914)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
<sup>18</sup>F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis. Radiology 2025 Yes
Healthcare needs of patients with metastatic cancer and impacts of social vulnerability: a multicentric cross-sectional study in France. BMC palliative care 2025 Yes
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nature medicine 2024 Yes
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal transduction and targeted therapy 2024 Yes
Comparison of novel PSMA-targeting [<sup>177</sup>Lu]Lu-P17-087 with its albumin binding derivative [<sup>177</sup>Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. European journal of nuclear medicine and molecular imaging 2024 Yes

Showing 5 of 3,914 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (6)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages